title: Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group.
abstract: BACKGROUND
  High-dose chemotherapy followed by autologous stem cell transplantation (AT) is accepted as first-line therapy for patients with multiple myeloma (MM), with very good tolerance and low mortality (2-3%).
  
  
  METHODS
  We tested repeated transplantation with different experimental maintenance therapies in patients with MM relapsing/progressing after first AT. Results were compared using intra-individual analyses, therefore inter-individual differences are excluded (T2 model).
  
  
  METHODS
  Between January 1997 and January 2003, 32 patients with relapsing/progressing MM after first AT were included in the pilot study, median follow-up was 75.2 months. They received the following experimental therapies: IL-2-activated PBSC (10 pts), pamidronate (4 pts), thalidomide (15 pts), consolidation chemotherapy CED (3 pts).
  
  
  RESULTS
  Sensitivity to C-VAD reinduction chemotherapy (4 cycles) was 50%, response to the second AT compared to the first was better in 7, the same in 16 and worse in 9 patients. Toxicity of the first and second transplantation was similar and usually did not exceed grade II (SWOG). Transplant-related mortality was 3% (1/32). Event-free survival after second AT (EFS II) is known in 22 patients; 7 have achieved prolongation of EFS II versus EFS I. In the whole group median EFS I was 15.7 months, median EFS II was 12.9 months, median overall survival (OS) was 79.1 months; 20/32 patients were alive at the time of analysis.
  
  
  CONCLUSIONS
  Repeated AT is a feasible and successful strategy in treatment of relapsing MM; response to second AT and toxicity were acceptable and similar to the first AT in our assessment.
authors.affiliation: Department of Internal Medicine-Hematooncology, University Hospital Brno, Czech Republic. akrivan@fnbrno.cz
authors.forename: A
authors.initials: A
authors.lastname: Krivanová
authors.forename: R
authors.initials: R
authors.lastname: Hájek
authors.forename: M
authors.initials: M
authors.lastname: Krejcí
authors.forename: V
authors.initials: V
authors.lastname: Scudla
authors.forename: K
authors.initials: K
authors.lastname: Indrák
authors.forename: J
authors.initials: J
authors.lastname: Bacovský
authors.forename: T
authors.initials: T
authors.lastname: Büchler
authors.forename: A
authors.initials: A
authors.lastname: Svobodník
authors.forename: Z
authors.initials: Z
authors.lastname: Adam
authors.forename: J
authors.initials: J
authors.lastname: Mayer
authors.forename: J
authors.initials: J
authors.lastname: Vorlícek
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018153:Czech Republic / Q000453:epidemiology; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery*; D010865:Pilot Projects; D033581:Stem Cell Transplantation / Q000379:methods / Q000706:statistics & numerical data*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents